On May 24, 2022, the Centers for Disease Control and Prevention issued a health advisory on COVID-19 Rebound After Paxlovid Treatment. The advisory is to alert health care providers and public health officials about the potential of COVID-19 rebound following Paxlovid treatment. It says, “Paxlovid continues to be recommended for early-stage treatment of mild to moderate COVID-19 among persons at high risk for progression to severe disease…A brief return of symptoms may be part of the natural history of SARS-CoV-2 (the virus that causes COVID-19) infection in some persons, independent of treatment with Paxlovid and regardless of vaccination status.”
The Office of the Assistant Secretary for Preparedness and Response (ASPR) provided a June 1, 2022, update on the Test to Treat initiative. The update states that Test to Treat is continuing to expand, building on existing sites and establishing new federally-supported sites in a coordinated effort by ASPR, FEMA and State, Tribal and Territorial governments. Types of federal support include testing, provider reimbursement and pharmacy services. Washington providers interested in being considered for this federal support should contact mcm@doh.wa.gov, with answers to the eight questions listed on the second page of the update if possible.
On June 1, 2022, the Washington State Department of Health Office of Emergency Preparedness communicated several updates on the Paxlovid therapeutic for WSHA to share with Washington providers. The DOH is continuing to distribute Paxlovid without limitations and with no anticipation of reduced support or supply shortages for the next couple months. Renal dosing of Paxlovid is available for allocation and ships in quantities of five. Providers should be aware that Paxlovid expiry dates were extended for the following lot numbers:
- Lot numbers: FL4516, FL4517 and FR7229 extended from 7/31/2022 to 10/31/2022.
- Lot number: FR9088 extended from 8/31/2022 to 11/30/2022
Providers interested in ordering Paxlovid should review the WA State Order Process for COVID-19 Therapeutics (Updated Feb. 10, 2022).
